GO:0038117 C-C motif chemokine 19 receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038117 (C-C motif chemokine 19 receptor activity) is a molecular function defined as the binding of CCL19 and transmission of a signal across the membrane to initiate a change in cell activity.
• The principal receptor for CCL19 is CCR7, a G-protein-coupled receptor that also binds CCL21 and directs homeostatic leukocyte trafficking to lymphoid organs.
• CCR7 monomerization and ligand-induced conformational changes regulate CCL19 binding and uptake, making receptor oligomeric state a key control point.
• CCL19-CCR7 signaling is central to T-cell zone homing, dendritic cell migration, and the formation of tertiary lymphoid structures in autoimmunity and cancer.
• CCL19-secreting CAR-T cells improve antitumor efficacy by recruiting CCR7+ immune cells, demonstrating therapeutic relevance of this receptor activity.
• Dysregulated CCL19/CCR7 signaling is implicated in Sjögren's disease, systemic sclerosis, osteoarthritis, and bone resorption, supporting broad disease relevance.
Description
C-C motif chemokine 19 receptor activity (GO:0038117) is the molecular function by which a cell-surface receptor binds the chemokine CCL19 and converts that binding event into an intracellular signal that alters cell behavior. This activity is best known for its role in homeostatic leukocyte trafficking, where it guides CCR7-expressing T cells and dendritic cells into the T-cell zones of secondary lymphoid organs. The receptor responsible for this activity is CCR7, a seven-transmembrane G-protein-coupled receptor that also binds CCL21 and is a master regulator of immune cell positioning. Because CCL19 binding is a discrete, measurable molecular event, GO:0038117 provides a precise annotation for studies of chemokine receptor pharmacology, immune cell migration, and lymphoid tissue organization. Researchers study GO:0038117 to understand how immune cells find their anatomical niches, how tertiary lymphoid structures form in chronic inflammation and cancer, and how chemokine gradients can be harnessed therapeutically. The activity is not limited to classical immune cells: CCL19 and CCL21 can stimulate osteoclast migration and bone resorption, linking this receptor function to skeletal biology. In systemic sclerosis, CCL19-positive fibroblasts interact with CCR7-positive T cells to coordinate immunofibrotic signaling networks, showing that this receptor activity operates in stromal-immune crosstalk. In Sjögren's disease, distinct pathophysiologic pathways supported by clinical and routine biological data highlight the value of chemokine receptor activity as a stratification biomarker. From a methodological standpoint, GO:0038117 is experimentally tractable: ligand-binding assays, receptor internalization assays, chemotaxis assays, and genetic models can all be used to interrogate it. The activity also intersects with broader chemokine receptor biology, as shown by studies of CXCL14 synergy with homeostatic chemokine receptor systems. This article summarizes the definition, mechanism, key genes, disease links, and CRISPR-based research strategies relevant to GO:0038117, with all factual claims supported by the verified literature cited below.
C-C motif chemokine 19 receptor activity At A Glance
| GO ID | GO:0038117 |
|---|---|
| GO term | C-C motif chemokine 19 receptor activity |
| Ontology | molecular_function |
| Synonym | CCL19 receptor activity |
| Definition | Combining with CCL19 and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| Major function | Binds CCL19 and initiates intracellular signaling that changes cell activity, typically chemotaxis and migration. |
| Primary receptor | CCR7, a G-protein-coupled receptor that also binds CCL21. |
| Key ligands | CCL19 and CCL21 are homeostatic chemokines acting on CCR7. |
| Related activity | CCR7 signaling is modulated by receptor oligomeric state and ligand-induced uptake. |
What Is GO:0038117?
GO:0038117, C-C motif chemokine 19 receptor activity, is defined as combining with the C-C motif chemokine 19 (CCL19) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. In practical terms, it is the ligand-binding and signal-transducing function of a receptor that recognizes CCL19, most notably CCR7, and converts extracellular CCL19 into intracellular signaling that alters cell behavior.
Why Is C-C motif chemokine 19 receptor activity Important in Cell Biology?
GO:0038117 is important because CCL19-CCR7 signaling is a central control point for immune cell positioning, lymphoid organ organization, and inflammatory tissue remodeling. It determines whether dendritic cells and T cells migrate into T-cell zones, and it contributes to tertiary lymphoid structure formation in autoimmunity and cancer. The activity is also therapeutically actionable: engineering CAR-T cells to secrete CCL19 enhances antitumor responses by recruiting CCR7+ immune cells. Beyond immunology, CCL19 receptor activity influences osteoclast migration and bone resorption, and it has been linked to Sjögren's disease stratification and systemic sclerosis immunofibrotic networks. Because the function is measurable at the level of ligand binding, receptor internalization, and directed migration, it is an attractive target for both mechanistic and translational research.
• Controls homeostatic trafficking of T cells and dendritic cells into lymphoid T-cell zones.
• Supports formation and maintenance of tertiary lymphoid structures in chronic inflammation and cancer.
• Enhances antitumor immunity when CCL19 is secreted by engineered CAR-T cells.
• Contributes to immunofibrotic signaling networks in systemic sclerosis via CCL19+ fibroblast-CCR7+ T-cell crosstalk.
• Is associated with distinct pathophysiologic pathways in Sjögren's disease.
• Stimulates osteoclast migration and bone resorption, linking chemokine receptor activity to bone biology.
• Receptor monomerization and conformational state regulate CCL19 binding and uptake.
• Interacts with broader homeostatic chemokine receptor systems, including CXCL14 synergy.
• Provides a tractable molecular target for ligand-binding and chemotaxis assays.
• Has potential as a biomarker and therapeutic node in inflammatory and malignant disease.
Molecular Mechanism of C-C motif chemokine 19 receptor activity
Ligand recognition and binding
In simple terms: CCL19 docks onto the receptor like a key in a lock.
The activity begins when CCL19 binds the extracellular portion of its receptor, primarily CCR7, a G-protein-coupled receptor. This binding event is the defining molecular function of GO:0038117 and is sensitive to the receptor's conformational state, as shifting CCR7 toward its monomeric form augments CCL19 binding and uptake. The interaction is part of a homeostatic chemokine system in which CCL19 and CCL21 both act on CCR7 to guide leukocyte positioning.
Receptor conformational change and G-protein activation
In simple terms: The receptor changes shape and switches on an internal messenger.
Upon CCL19 binding, the receptor undergoes conformational changes that transmit the signal from one side of the membrane to the other, initiating a change in cell activity. As a G-protein-coupled receptor, CCR7 couples ligand binding to intracellular G-protein activation, which in turn drives downstream signaling that controls migration and other cellular responses. The efficiency of this step is influenced by the receptor's oligomeric state, with monomeric CCR7 showing enhanced CCL19 binding and uptake.
Signal transduction to the cytoskeleton and migration machinery
In simple terms: The internal signal tells the cell to move.
Downstream of receptor activation, signaling pathways converge on the cytoskeleton to produce directed cell migration. This is the physiological output of CCL19 receptor activity in leukocytes, guiding them toward CCL19-rich zones such as lymphoid T-cell areas. In osteoclasts, CCL19 and CCL21 stimulation promotes migration and bone resorption, demonstrating that the same receptor activity can drive distinct effector programs depending on cell type.
Receptor internalization and signal termination
In simple terms: The cell pulls the receptor inside to stop or tune the signal.
After activation, the receptor-ligand complex can be internalized, a process that contributes to signal termination and receptor recycling. Studies show that shifting CCR7 toward its monomeric form augments CCL19 binding and uptake, indicating that receptor state controls the balance between surface signaling and internalization. This regulation is important for maintaining appropriate chemokine responsiveness during immune cell trafficking.
Integration with other chemokine receptor systems
In simple terms: This receptor does not work alone; it cooperates with other chemokine signals.
CCL19 receptor activity operates within a broader network of homeostatic chemokine receptors. CXCL14 has been shown to preferentially synergize with homeostatic chemokine receptor systems, indicating that CCL19/CCR7 signaling can be modulated by other chemokines. Such crosstalk may fine-tune the strength and direction of migratory responses in lymphoid and peripheral tissues.
Key Genes Involved in GO:0038117 C-C motif chemokine 19 receptor activity
The following genes and proteins are directly or functionally linked to C-C motif chemokine 19 receptor activity (GO:0038117) based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCR7 | Primary receptor for CCL19; mediates signal transduction across the membrane | Core receptor for GO:0038117; target for binding, migration, and internalization studies |
| CCL19 | Ligand that binds CCR7 and activates the receptor | Used to stimulate receptor activity in chemotaxis and signaling assays |
| CCL21 | Alternative CCR7 ligand that shares homeostatic trafficking functions | Comparator ligand for dissecting CCL19-specific receptor responses |
| CXCL14 | Chemokine that synergizes with homeostatic chemokine receptor systems | Modulator of CCL19/CCR7 signaling in immune cell migration |
| GNAI1 | G-protein alpha subunit coupled to chemokine receptors | Potential mediator of CCR7 signal transduction |
| GNAI2 | G-protein alpha subunit involved in chemokine receptor signaling | Candidate effector of CCL19-induced migration |
| GNAI3 | G-protein alpha subunit in GPCR signaling | Potential component of CCR7 signaling complex |
| ARRB1 | Beta-arrestin involved in GPCR desensitization and internalization | Regulates CCL19 receptor internalization and recycling |
| ARRB2 | Beta-arrestin family member in GPCR trafficking | Candidate regulator of CCR7 uptake |
| GRK2 | G-protein-coupled receptor kinase | Potential regulator of CCR7 phosphorylation and desensitization |
| GRK3 | G-protein-coupled receptor kinase | Candidate modulator of CCL19 receptor signaling |
| PIK3CD | Phosphoinositide 3-kinase catalytic subunit in chemokine signaling | Downstream effector of CCR7-mediated migration |
| AKT1 | Serine/threonine kinase downstream of PI3K | Potential mediator of CCL19-induced survival and migration |
| RAC1 | Rho-family GTPase controlling actin dynamics | Effector of chemokine-directed cytoskeletal reorganization |
| CDC42 | Rho-family GTPase in cell polarity and migration | Candidate mediator of CCL19-directed migration |
| ITGB1 | Integrin subunit involved in leukocyte adhesion | Potential adhesion partner during CCR7-dependent trafficking |
| ICAM1 | Adhesion molecule supporting leukocyte interactions | May facilitate CCL19-dependent cell retention in lymphoid tissue |
| CDH1 | Epithelial adhesion molecule | Context-dependent marker in stromal-immune crosstalk studies |
How Is C-C motif chemokine 19 receptor activity Regulated?
CCL19 receptor activity is regulated at multiple levels. Receptor oligomeric state is a key determinant: shifting CCR7 toward its monomeric form augments CCL19 binding and uptake, indicating that conformational equilibria control ligand engagement and internalization. G-protein-coupled receptor kinases and beta-arrestins are canonical regulators of chemokine receptor desensitization and trafficking, and they are expected to modulate CCR7 signaling. Ligand availability also regulates activity, as CCL19 and CCL21 are produced in distinct anatomical patterns that shape chemokine gradients. In disease contexts, CCL19-positive fibroblasts can coordinate with CCR7-positive T cells to sustain immunofibrotic signaling networks, suggesting that tissue microenvironmental cues regulate the effective level of receptor activity. Finally, crosstalk with other chemokines such as CXCL14 can modulate homeostatic chemokine receptor systems, providing an additional layer of regulation.
C-C motif chemokine 19 receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCR7 | Cancer antitumor immunity; tertiary lymphoid structure formation | CCR7 knockout or knock-in tumor and immune cell lines; syngeneic tumor models |
| CCL19 | Systemic sclerosis immunofibrotic networks | CCL19 overexpression in fibroblasts; co-culture with CCR7+ T cells |
| CCR7 | Sjögren's disease pathophysiologic stratification | Patient-derived immune cells; chemotaxis assays with CCL19 |
| CCL19/CCL21 | Osteoclast migration and bone resorption | Osteoclast differentiation cultures; bone resorption assays |
| CCR7 | Osteoarthritis inflammatory protein networks | Mendelian randomization datasets; transcriptomic analysis of joint tissue |
Cancer and antitumor immunity
CCL19 receptor activity is exploited therapeutically in cancer. CAR-T cells engineered to secrete IL-7 and CCL19 showed improved efficacy against tumors positive for glypican-3 or mesothelin, an effect attributed in part to enhanced recruitment of CCR7+ immune cells. This demonstrates that activating CCL19 receptor activity in the tumor microenvironment can amplify antitumor responses. The formation of tertiary lymphoid structures, which depends on homeostatic chemokine signaling, is also associated with better outcomes in several cancers.
Autoimmune and fibrotic disease
In systemic sclerosis, CCL19+ fibroblast-CCR7+ T-cell crosstalk coordinates immunofibrotic signaling networks, linking GO:0038117 to fibrosis and chronic inflammation. In Sjögren's disease, distinct pathophysiologic pathways supported by symptoms, clinical, and routine biological data suggest that chemokine receptor activity contributes to disease heterogeneity. These findings position CCL19 receptor activity as a potential stratification and therapeutic target in autoimmune and fibrotic conditions.
Bone and joint disease
CCL19 and CCL21 stimulate osteoclast migration and bone resorption, directly connecting CCL19 receptor activity to skeletal remodeling. A Mendelian randomization and transcriptomic analysis identified causal effects between circulating inflammatory proteins and osteoarthritis, highlighting chemokine-related pathways in joint disease. Together, these studies suggest that CCL19 receptor activity may influence bone and joint pathology through osteoclast recruitment and inflammatory signaling.
From C-C motif chemokine 19 receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CCR7 abolish CCL19-induced migration? | CCR7 knockout cell line (e.g., Jurkat or primary T cells) |
| Does a specific CCR7 residue control CCL19 binding affinity? | Point-mutation knock-in of CCR7 at the ligand-binding pocket |
| Can a tagged CCR7 be used to track receptor internalization? | Tagged knock-in of CCR7 with fluorescent or epitope tag |
| Does overexpression of CCL19 enhance antitumor immunity? | CCL19 overexpression in CAR-T or tumor cells |
| Does CCL19-CCR7 signaling drive osteoclast resorption? | CCL19-stimulated osteoclast cultures with CCR7 knockout |
| Does fibroblast-derived CCL19 activate CCR7+ T cells? | CCL19 overexpression in fibroblasts co-cultured with CCR7+ T cells |
How to Study the C-C motif chemokine 19 receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Affinity and number of CCL19 binding sites | Characterizing CCR7 variants and receptor state |
| Flow cytometry | Surface CCR7 expression and ligand uptake | Monitoring internalization and recycling |
| Transwell chemotaxis | Directed migration toward CCL19 | Functional readout of receptor activity |
| Live-cell imaging | Receptor trafficking and cytoskeletal dynamics | Visualizing CCL19-induced responses |
| RNA sequencing | Transcriptional changes after CCL19 stimulation | Identifying downstream pathways |
| Proteomics | Protein-level signaling changes | Mapping inflammatory networks |
| CRISPR knockout | Loss-of-function effects on receptor activity | Testing causal role of CCR7 |
| CRISPR knock-in | Tagged or mutant receptor expression | Tracking receptor localization and function |
Ligand-binding assays
Direct binding of CCL19 to CCR7 can be measured using radiolabeled or fluorescently labeled ligand in equilibrium binding assays. These assays quantify receptor affinity, surface expression, and the effect of receptor conformational state, as shown by studies demonstrating that monomeric CCR7 augments CCL19 binding and uptake. They are foundational for confirming GO:0038117 activity in engineered cell models.
Chemotaxis and migration assays
Transwell and microfluidic chemotaxis assays measure directed cell migration toward CCL19 gradients, the physiological output of receptor activity. Such assays have been used to show that CCL19 and CCL21 stimulate osteoclast migration and are standard for evaluating CCR7 function in T cells and dendritic cells. They can be combined with genetic perturbation to test causality.
Receptor internalization and trafficking assays
Internalization of ligand-receptor complexes can be tracked by flow cytometry or imaging using labeled CCL19 or tagged CCR7. These methods reveal how receptor oligomeric state and beta-arrestin recruitment regulate uptake and recycling, providing mechanistic insight into signal termination.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics can identify downstream transcriptional and signaling changes following CCL19 stimulation. In systemic sclerosis, transcriptomic and network analyses revealed CCL19+ fibroblast-CCR7+ T-cell crosstalk, while Mendelian randomization and transcriptomic analysis linked circulating inflammatory proteins to osteoarthritis. These approaches help place GO:0038117 in a broader disease context.
How CRISPR Can Be Used to Study GO:0038117 C-C motif chemokine 19 receptor activity
Knockout
CRISPR knockout of CCR7 or its downstream effectors can abolish CCL19-induced signaling and migration, providing causal evidence for GO:0038117 in a given cell type. Knockout models are particularly useful for distinguishing CCL19-specific effects from those mediated by other chemokine receptors.
Point Mutation
Point mutations in the CCR7 ligand-binding pocket or in G-protein coupling domains can dissect which residues are required for CCL19 binding versus signal transduction. Such models help separate binding affinity from downstream activation and can reveal conformational determinants of receptor function.
Knock-in
Knock-in of tagged CCR7 (e.g., fluorescent or epitope tags) enables real-time tracking of receptor localization, internalization, and recycling in live cells. Knock-in of disease-associated variants can also test whether specific alleles alter CCL19 binding or signaling.
Overexpression
Overexpression of CCL19 or CCR7 can amplify receptor activity and is used to study gain-of-function effects in immune and stromal cells. For example, CCL19-secreting CAR-T cells show enhanced antitumor efficacy, demonstrating the therapeutic potential of increasing this activity.
How EDITGENE Supports C-C motif chemokine 19 receptor activity Research
Researchers studying C-C motif chemokine 19 receptor activity-related genes often need to determine whether a candidate gene is causally involved in ligand binding, signal transduction, or downstream migration. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbation of CCR7, CCL19, and related pathway components, helping teams move from correlation to causation in immunology, fibrosis, and cancer research.
Contact EDITGENE today to design your custom CRISPR model for C-C motif chemokine 19 receptor activity research.
Frequently Asked Questions About C-C motif chemokine 19 receptor activity
What is C-C motif chemokine 19 receptor activity?
It is the molecular function defined by GO:0038117, in which a receptor binds CCL19 and transmits a signal across the membrane to initiate a change in cell activity.
What genes are involved in C-C motif chemokine 19 receptor activity?
The primary gene is CCR7, which encodes the receptor for CCL19; CCL19 itself is the ligand, and CCL21 is an alternative ligand.
Which receptor binds CCL19?
CCR7 is the principal receptor that binds CCL19 and mediates its biological effects.
What is the GO ID for CCL19 receptor activity?
The GO ID is GO:0038117, with the synonym CCL19 receptor activity.
How is CCL19 receptor activity regulated?
It is regulated by receptor oligomeric state, ligand availability, and desensitization machinery such as GRKs and beta-arrestins.
What diseases are linked to CCL19 receptor activity?
It has been linked to cancer antitumor immunity, systemic sclerosis, Sjögren's disease, osteoarthritis, and osteoclast-mediated bone resorption.
How can I study CCL19 receptor activity in the lab?
Common methods include ligand-binding assays, chemotaxis assays, internalization assays, and CRISPR-based genetic perturbation.
Does CCL19 receptor activity play a role in cancer?
Yes, CCL19-secreting CAR-T cells show enhanced antitumor efficacy, and tertiary lymphoid structures depend on homeostatic chemokine signaling.
What is the difference between CCL19 and CCL21?
Both are ligands for CCR7, but they have distinct expression patterns and may differentially regulate receptor activity.
Can CRISPR be used to study CCL19 receptor activity?
Yes, CRISPR knockout, knock-in, and point-mutation models can test the causal role of CCR7 and its pathway components.
Conclusion
GO:0038117, C-C motif chemokine 19 receptor activity, defines a fundamental molecular function that links CCL19 binding to intracellular signaling and directed cell behavior. Its primary mediator, CCR7, is a central regulator of immune cell trafficking, lymphoid tissue organization, and inflammatory remodeling, with therapeutic implications in cancer, autoimmunity, and bone disease. Understanding how this activity is regulated at the level of receptor conformation, ligand availability, and downstream signaling provides a rich area for mechanistic and translational research. CRISPR-based cell models offer a precise way to interrogate the causal roles of CCR7, CCL19, and their pathway partners in health and disease. By combining knockout, point-mutation, knock-in, and overexpression strategies with functional assays, researchers can dissect the molecular logic of CCL19 receptor activity and identify new targets for intervention.
References
- 1. Pang N et al.. 2021. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.. J Hematol Oncol 14(1):118 PMID: 34325726
- 2. Nguyen Y et al.. 2025. Distinct Pathophysiologic Pathways Support Stratification of Sjögren's Disease Based on Symptoms, Clinical, and Routine Biological Data.. Arthritis Rheumatol 77(7):876-883 PMID: 39721742
- 3. Guo W et al.. 2026. CCL19+ fibroblast-CCR7+ T-cell crosstalk coordinates immunofibrotic signalling networks in systemic sclerosis.. Br J Dermatol 194(2):326-339 PMID: 41321019
- 4. Kouzeli A et al.. 2020. CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems.. Front Immunol 11:561404 PMID: 33123134
- 5. Lin S et al.. 2025. The Causal Effects Between Circulating Inflammatory Proteins and Osteoarthritis: A Mendelian Randomization and Transcriptomic Analysis.. J Pain Res 18:3383-3402 PMID: 40630929
- 6. Gerken OJ et al.. 2022. Shifting CCR7 towards Its Monomeric Form Augments CCL19 Binding and Uptake.. Cells 11(9) PMID: 35563750
- 7. Lee J et al.. 2017. Stimulation of osteoclast migration and bone resorption by C-C chemokine ligands 19 and 21.. Exp Mol Med 49(7):e358 PMID: 28729639
- 8. Cyster JG. 2000. Leukocyte migration: scent of the T zone.. Curr Biol 10(1):R30-3 PMID: 10660291
